J Biol Chem, Vol. 275, Issue 6, 3819-3826, February 11, 2000
Release of Insulin Receptor Substrate Proteins from an
Intracellular Complex Coincides with the Development of Insulin
Resistance*
Sharon F.
Clark
,
Juan-Carlos
Molero
, and
David E.
James
§
From the Centre for Molecular and Cellular Biology, Department of
Physiology and Pharmacology, University of Queensland,
Brisbane, 4072 Australia
 |
ABSTRACT |
Insulin receptor substrate (IRS) proteins are
major substrates of the insulin receptor (IR). IRS-1 associates with an
insoluble multiprotein complex, possibly the cytoskeleton, in
adipocytes. This localization may facilitate interaction with the IR at
the cell surface. In the present study, we examined the hypothesis that
the release of IRS proteins from this location may be a mechanism for
insulin desensitization. We show that a second IRS protein, IRS-2, is
associated with a multiprotein complex in adipocytes with similar
characteristics to the IRS-1 complex. Insulin treatment (15-60 min)
caused the release of IRS-1 and IRS-2 from this complex (high speed
pellet; HSP) into the cytosol, whereas the level of tyrosyl-phosphorylated IRS proteins remained constant. Chronic insulin
treatment resulted in a dramatic reduction in IRS-1 and IRS-2 in the
HSP, eventually (>2 h) leading to IRS protein degradation and
decreased levels of tyrosyl-phosphorylated IRS proteins. Okadaic acid,
which rapidly induces insulin resistance in adipocytes independently of
IR function, caused an almost quantitative release of IRS-1 into the
cytosol commensurate with a significant reduction in tyrosyl-phosphorylated IRS proteins. Platelet-derived growth factor, a
factor known to compromise insulin signaling, caused a more moderate
release of IRS proteins from the HSP. Collectively, these results
suggest that the assembly of IRS-1/IRS-2 into a multiprotein complex
facilitates coupling to the IR and that the regulated release from this
location may represent a novel mechanism of insulin resistance.
 |
INTRODUCTION |
The insulin receptor
(IR)1 is a member of the
tyrosine kinase growth factor receptor family (1). One property that
distinguishes the IR from other growth factor receptors is its ability
to induce the tyrosine phosphorylation of a family of intracellular
signaling molecules referred to as insulin receptor substrate (IRS)
proteins (2-5). IRS proteins contain a pleckstrin homology domain and a phosphotyrosine binding domain, both of which are required for the
efficient tyrosine phosphorylation of these proteins by the activated
insulin receptor tyrosine kinase (6, 7). The first member of the IRS
family to be identified, IRS-1, encodes a 160-kDa protein that is
highly expressed in physiologically insulin-responsive tissues such as
adipocytes and muscle cells and has been implicated in the control of a
number of insulin-sensitive metabolic pathways including glucose
transport, lipid deposition, and glycogen synthesis (8). In response to
insulin, the phosphorylation of multiple tyrosine residues within the C
terminus of IRS-1 by the IR leads to the generation of highly specific
binding sites for a number of Src homology 2 domain-containing
downstream signaling molecules such as phosphatidylinositide (PI)
3-kinase, Syp, Nck, Fyn, and Grb-2 (8-10). PI 3-kinase appears to be a
central insulin-signaling molecule, because inhibition of its activity
by either pharmacological agents or dominant-negative mutants
profoundly abrogates several biological responses to this hormone
(11-14). In basal cells, IRS-1 is also highly phosphorylated on serine
and threonine (Ser/Thr) residues, and insulin acutely stimulates a
further increase in IRS-1 Ser/Thr phosphorylation (4, 15). The
signaling function of IRS-1 Ser/Thr phosphorylation is unknown,
although this may regulate the docking of other types of signaling
molecules such as 14-3-3 proteins (16, 17).
Defects within insulin signaling pathways comprise a major locus for
the development of insulin resistance in disease states such as
non-insulin-dependent diabetes mellitus (18). Certain forms
of insulin resistance, such as that induced by tumor necrosis factor-
, okadaic acid, or chronic insulin treatment, may be due to
uncoupling of the IR activity toward IRS-1 (19-21). While the molecular basis for this defect is unclear, a common observation in
cells subjected to these conditions is that IRS-1 becomes
hyperphosphorylated on serine and threonine residues and various
intracellular Ser/Thr kinases, including glycogen synthase kinase-3,
protein kinase C-
, mitogen-activated protein kinase, and protein
kinase B/Akt, have been implicated in mediating this effect (22-28).
The decline in insulin sensitivity invoked by tumor necrosis factor-
has recently been attributed to a dominant negative effect exerted by
hyperphosphorylated IRS-1 upon the IR intrinsic tyrosine kinase (19).
However, neither okadaic acid nor chronic insulin treatment appear to
disrupt IR tyrosine kinase activity in response to acute insulin
activation (20, 21, 24). These latter observations suggest that other
mechanisms may operate to induce insulin resistance.
We have recently provided evidence to suggest that IRS-1 is enriched in
a cytoskeletal fraction in adipocytes that is insoluble in a range of
nonionic detergents (29). This accounts for early reports suggesting
that IRS-1 is bound to membranes, because the cytoskeletal fraction
co-fractionates with microsomal membranes during ultracentrifugation
(30, 31). The anchoring of IRS-1 to the cytoskeleton may be of
particular importance to the efficacy of insulin signaling by providing
a platform for localizing IRS-1 within proximity to the insulin
receptor. This arrangement may also provide a robust link between IRS-1
and downstream signaling proteins such as PI 3-kinase, which also
appears to associate with this insoluble fraction (29). One functional
consequence of this spatial localization is that it may create a unique
site for the generation of specific signals required for insulin
action. Consistent with the latter notion, platelet-derived growth
factor (PDGF) also activates PI 3-kinase in adipocytes but has no
significant effect on PI 3-kinase-dependent functions in
these cells, including glucose transport and glycogen synthesis
(32).
It has previously been reported that IRS-1 exists in at least two
distinct pools in adipocytes: the cytoskeletal component and the
cytosol (31, 33). Furthermore, short term insulin treatment triggers
the release of IRS-1 from the cytoskeletal fraction into the cytosol
(31). It has been argued that the cytoskeletal component represents the
functional pool of IRS-1, because most of the tyrosyl-phosphorylated
IRS-1 is found in this pool, and there is a net increase in PI 3-kinase
in this fraction in response to insulin (34). Hence, it may be
postulated that the deactivation of IRS-1 corresponds to its
translocation from this fraction into the cytosol. This model raises
the possibility that the cytosolic pool of IRS-1 is nonfunctional
presumably due to its inaccessibility to the IR. Therefore,
inappropriate accumulation of IRS-1 in the cytosol may disengage this
protein from the receptor, resulting in a state of insulin resistance.
In the present study, we have tested the notion that the intracellular
location of IRS-1 can be modified under conditions that normally cause
insulin resistance and/or alter insulin signaling potential. In
addition, we have extended this hypothesis to include the IRS-1
homologue, IRS-2, which is also expressed in 3T3-L1 adipocytes. Our
results show that a significant proportion of IRS-1 and IRS-2 are found
in a detergent-resistant insoluble fraction that has properties
analogous to the cytoskeleton. Moreover, IRS proteins translocate from
this location into the cytosol following exposure of adipocytes to chronic insulin treatment or okadaic acid or PDGF. These data suggest
that the intracellular location of IRS proteins is regulated in a way
that may influence insulin action.
 |
EXPERIMENTAL PROCEDURES |
Reagents and Antibodies--
All tissue culture media was
purchased from Life Technologies, Inc., except fetal calf serum, which
was obtained from Trace Biosciences (Clayton, Australia). Insulin was
obtained from Calbiochem, and PDGF.B was from Life Technologies, Inc.
Bovine serum albumin was purchased from ICN (Costa Mesa, CA). Unless
specified, all other reagents were from Sigma. The GLUT4 polyclonal
antibody (R820) was raised against a synthetic peptide as described
previously (35). The anti-phosphotyrosine monoclonal antibody (4G10)
was kindly provided by Dr. B. Druker (Oregon Health Sciences
University, Portland, OR), and polyclonal antibodies raised against
Akt-2 were provided by Dr. M. Birnbaum (Howard Hughes Medical
Institute, Philadelphia, PA). All other antibodies used in this study
were purchased from the following sources: anti-IRS-1 polyclonal
antibody from Santa Cruz Biotechnology Inc. (Santa Cruz, CA); anti-p85 and anti-IRS-2 polyclonal antibodies from Upstate Biotechnology Inc.
(Lake Placid, NY); anti-hemagglutinin (HA) monoclonal antibody from
Babco (Richmond, CA); peroxidase-coupled secondary antibodies from
Amersham Pharmacia Biotech (Little Chalfont, United Kingdom).
Construction of HA-IRS-1--
Full-length mouse IRS-1 cDNA
in pBluescriptSK, generously provided by Drs. S. Keller and G. Lienhard
(Dartmouth Medical School, Hanover, NH), was used as template in a
polymerase chain reaction to generate a construct encoding IRS-1 tagged
at the C terminus with the HA epitope (HA-IRS-1). In this reaction, the
forward primer consisted of the pBluescript sequencing primer, T7,
whereas the reverse primer was comprised of the following sequence:
5'-CTGCGGTCGACTAAGCGTAATCTGGAACATCGTATGGGTAAGCTTGACGATCCTCTGGCTGCTTCTGGAAGCTGATGCTGGC-3' (Pacific Oligos, Lismore, Australia). A cDNA fragment
encoding the entire sequence of HA-IRS-1 was then amplified using
standard polymerase chain reaction protocols. The amplified product was isolated, digested with SalI, and subcloned into
SalI sites of a eukaryotic expression vector, pMEX (36).
Clones carrying the insert in the desired orientation were verified by
restriction mapping.
Cell Culture and Treatments--
3T3-L1 fibroblasts were
cultured and differentiated into adipocytes as described previously
(37). Cells were serum-starved in Dulbecco's modified Eagle's medium
supplemented with 0.1% bovine serum albumin and 2 mM
glutamine for 2 h at 37 °C and subsequently incubated with
insulin (1 µM) for 0.25 h (acute) or for 0.25, 1, 2, or 4 h (chronic) or with PDGF (50 ng/ml) for 1 h at 37 °C. Where indicated, cells were incubated with wortmannin (100 nM) for 15 min and then insulin (1 µM) and
wortmannin for 1 h at 37 °C. Medium was replaced with medium
containing fresh wortmannin (100 nM) and insulin (1 µM) 30 min prior to harvesting cells. In other
experiments, cells were incubated with okadaic acid (2.5-5.0 µM) for 30 min, during which insulin (1 µM)
was added to the incubation medium for the last 15 min. In glucose
uptake assays, 3T3-L1 adipocytes were serum-starved in Krebs-Ringer
phosphate buffer (2.5 mM HEPES (pH 7.4), 120 mM
NaCl, 6 mM KCl, 1.2 mM MgSO4, 10 mM CaCl2, 0.4 mM
NaH2PO4, 0.6 mM
Na2HPO4), KRP, containing 0.1% bovine serum albumin and 3.0 mM sodium pyruvate, for 2 h at
37 °C. Cells were then incubated with PDGF (50 ng/ml) for 1 h
and subsequently incubated with insulin (1 µM) for a
further 15 min.
CHO cells overexpressing the insulin receptor (CHO-IR) were kindly
donated by Dr. M White (Harvard Medical School, Boston, MA) and were
maintained in culture as described previously (29). Prior to
transfection, cells were seeded in 60-mm dishes and grown for a further
24 h to achieve 60-80% confluence. Transient transfections were
performed by incubating cells in medium (Dulbecco's modified Eagle's
medium, nonessential amino acids, 2 mM
L-glutamine) containing 6 µg of HA-IRS-1/pMEX and 30 µl
of Lipofectamine reagent for 5 h at 37 °C. Transfection medium
was then replaced with CHO cell culture media, and cells were grown to
100% confluence. Transfected cells were subsequently serum-starved and
exposed to chronic insulin treatment as described above for adipocytes.
In preliminary experiments, immunofluorescence studies of CHO-IR cells
transfected with HA-IRS-1 cDNA showed that at least 20-30% of
cells expressed full-length HA-IRS-1 protein.
Cell Fractionation--
After incubation with the appropriate
agents, 3T3-L1 adipocytes were washed three times with ice-cold HES
buffer (20 mM HEPES (pH 7.4), 1 mM EDTA, 250 mM sucrose) and homogenized in the same buffer supplemented
with phosphatase and protease inhibitors (2 mM sodium
orthovanadate, 10 mM sodium fluoride, 1 mM
tetra-sodium pyrophosphate, 1 mM ammonium
molybdate, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 250 µM phenylmethylsulfonyl fluoride). Subcellular fractions
were isolated by differential centrifugation as previously detailed
(37). All procedures were performed at 4 °C. Briefly, cell
homogenates were centrifuged at 13,000 × g for 20 min.
The resulting pellet was then resuspended in HES buffer and layered onto a 1.12 M sucrose cushion as described by Piper
et al. (37). After centrifugation at 77,000 × g for 1 h, the plasma membrane fraction was collected
from the 1.12 M sucrose interface. The supernatant from the
13,000 × g centrifugation step was subjected to
centrifugation at 30,000 × g for 30 min to pellet the
high density microsomal fraction. The resultant supernatant was
subjected to further centrifugation at 175,000 × g for
75 min to obtain the high speed pellet (HSP). The supernatant from this
centrifugation step was designated the cytosol fraction. The membrane
pellets were solubilized with 1% SDS in PBS. In some experiments, the HSP fraction from 3T3-L1 adipocytes was resuspended and incubated in
HES containing 1% Triton X-100 (Pierce) for 1 h on ice. Insoluble material was collected by centrifugation at 175,000 × g for 75 min at 4 °C, and the resultant pellet was
solubilized in 1% SDS in PBS.
CHO-IR cells overexpressing HA-IRS-1 were subjected to chronic insulin
treatment, and the HSP from these cells was obtained as described
previously (29) with some modifications. All steps were performed at
4 °C. Cells were washed in ice-cold HES and then homogenized in HES
buffer containing phosphatase and protease inhibitors by passage
through a 22-gauge needle. The homogenate was subjected to
centrifugation at 17,500 × g for 15 min to remove high
density microsomes, plasma membranes, mitochondria/nuclei, and cell
debris. The supernatant was then centrifuged at 175,000 × g for 75 min. The resultant supernatant was designated the
cytosol. The pellet (HSP), was solubilized in 1% SDS in PBS.
Immunoblotting and Densitometry Analysis--
The amount of
protein present in all samples was determined using BCA reagent
(Pierce). Samples were subjected to SDS-PAGE (38) and transferred to
Immobilon-P polyvinylidene difluoride membranes (Millipore Corp.,
Bedford, MA). Membranes were blocked with 3% bovine serum albumin in
TBST buffer (20 mM Tris·HCl (pH 7.6), 150 mM
NaCl, 0.05% Tween 20) (anti-phosphotyrosine antibody) or with 5% skim
milk powder in PBS buffer (all other antibodies). The membranes were
incubated with primary antibody, washed, and then incubated with the
appropriate horseradish peroxidase-coupled secondary antibody for 30 min at room temperature. Immunoreactive proteins were visualized by
autoradiography using enhanced chemiluminescence (Supersignal, Pierce,
or ECL Plus, Amersham Pharmacia Biotech), according to the instructions
from the manufacturer. The protein bands were quantified by
densitometry (GS-700 Imaging densitometer, Bio-Rad) using nonsaturated
exposed x-ray films. Statistical analysis of the data was performed
using Microsoft Excel software. All data are presented as the mean value.
Glucose Uptake Assays--
2-Deoxy-[3H]glucose
uptake was measured as described previously (39). Briefly, 3T3-L1
adipocytes were treated in the absence or presence of growth factor in
950 µl of KRP containing 1% bovine serum albumin and 3.0 mM sodium pyruvate. The assay was initiated by adding 50 µl of 1 mM 2-deoxy-[3H]glucose (20 µCi/mmol)/KRP and, after 3 min, was terminated by washing cells
rapidly three times with ice-cold PBS. Cells were subsequently
solubilized in 1% Triton X-100, and 3H was quantitated by
scintillation counting (Packard 1900CA liquid scintillation analyzer,
Packard Instrument Co.). Glucose uptake was measured in duplicate in
all treatments. Nonspecific uptake of 2-deoxy-[3H]glucose
was determined by adding 50 µM cytochalasin B to the appropriate controls prior to the commencement of assays.
 |
RESULTS |
Subcellular Distribution of IRS-1 Versus IRS-2 in 3T3-L1
Adipocytes--
In basal adipocytes, IRS-1 is enriched in a microsomal
fraction, often referred to as the low density microsomes (31, 33, 40).
In addition to intracellular membranes that contain the insulin-regulatable glucose transporter, GLUT4, the low density microsomes fraction also contains cytoskeleton and other large protein
complexes. In fact, >60% of the protein in this fraction is insoluble
in nonionic detergents, so we now refer to this fraction as the high
speed pellet, or HSP (41). In contrast to membrane proteins such as
GLUT4, IRS-1 remains insoluble following treatment of the HSP with
nonionic detergents, and it does not have a buoyant density that
enables it to float up through a 50% sucrose solution (29). Based on
these data, we proposed that IRS-1 is either attached to the
cytoskeleton or found in a large protein complex that enables it to be
pelleted during high speed centrifugation.
In certain cellular contexts, IRS-2 may functionally substitute for
IRS-1 in mediating insulin action (42). In 3T3-L1 adipocytes, the
subcellular distribution of IRS-2 is indistinguishable from IRS-1 (Fig.
1A). Consistent with recent
studies (34, 43), we observed a significant amount (60-80% of the
total) of both IRS-1 and IRS-2 in the HSP fraction in basal adipocytes.
Low levels were found in the plasma membrane and high density microsome
fractions, possibly due to contamination of these fractions with
HSP-derived material. Significant levels (20-40%) of both IRS-1 and
IRS-2 were found in the cytosol under basal conditions. Consistent with previous studies (31, 34), both IRS-1 and IRS-2 were released from the
HSP into the cytosol upon acute treatment of the cells with insulin
(Fig. 1A). The HSP pool of IRS-2 exhibited similar biochemical properties to that of IRS-1, in that it remained insoluble following treatment with the nonionic detergent, Triton X-100 (Fig.
1B). In addition, flotation analysis of the HSP as described previously (29) showed that, in contrast to membrane-associated proteins but identical to IRS-1, IRS-2 does not float up through a 50%
sucrose solution (data not shown). These data are consistent with a
model where the HSP pool of both IRS-1 and IRS-2 are not membrane-associated.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 1.
IRS-1 and IRS-2 are enriched in a
detergent-insoluble high speed pellet fraction isolated from
adipocytes. Adipocytes were incubated in the absence ( ) or
presence (+) of insulin (1 µM) for 15 min, homogenized,
and subjected to differential centrifugation to yield fractions
enriched in plasma membranes (PM), high density microsomes
(HDM), cytosol (CYT), and a high speed pellet
(HSP) fraction. A, fractions (20 µg of protein)
were resolved by SDS-PAGE and immunoblotted with antisera specific for
IRS-1 and IRS-2. B, the HSP fraction isolated from basal
( ) or insulin-treated (+) adipocytes was incubated in HES buffer (20 mM HEPES, 1 mM EDTA, 250 mM
sucrose, pH 7.4) or HES buffer containing 1% Triton X-100
(Tx-100) at 4 °C for 1 h, and the insoluble material
was pelleted by centrifugation at 175,000 × g. The
resultant pellets were analyzed by SDS-PAGE and immunoblotted with
antibodies against IRS-1 and IRS-2.
|
|
Effects of Chronic Insulin Treatment on the Subcellular
Distribution of IRS Proteins--
As depicted in Fig. 1A
and described in more recent studies (34), both IRS-1 and IRS-2 undergo
acute insulin-stimulated release from the HSP into the cytosol. With
extended insulin treatment (15-60 min), there was significant loss of
immunoreactive IRS-1 and IRS-2 from the HSP (>80%), but the amount of
tyrosine-phosphorylated IRS proteins remained fairly constant during
this time (Fig. 2, A and
B). This suggests that a relatively small component of the total IRS protein pool is tyrosine-phosphorylated in response to
insulin at steady state and that this pool of IRS proteins is
maintained despite a marked loss of immunoreactive protein from the HSP
fraction following prolonged exposure to insulin. The amount of IRS
proteins in the HSP continued to decline in response to long term
exposure to insulin, and it was not until the cells had been incubated
in the presence of insulin for up to 4 h before there was a
significant decrease in tyrosine-phosphorylated IRS proteins in the HSP
fraction (Fig. 2, A and B). This corresponded to
the time of onset of insulin resistance as determined by the amount of
the insulin-regulatable glucose transporter, GLUT4, in the plasma
membrane (Fig. 2D), and the amount of immunoreactive p85 in
the HSP fraction that also declined at the 4-h time point (Fig.
2A). A similar time course of insulin-induced insulin
resistance in 3T3-L1 adipocytes has been reported by other groups (21, 24).

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 2.
Effects of chronic insulin treatment on the
subcellular distribution of IRS-1, IRS-2, PI 3-kinase, and GLUT4 in
3T3-L1 adipocytes. 3T3-L1 adipocytes were incubated with insulin
(1 µM) for various times (0-4 h). Cells were
homogenized, and the cytosol and high speed pellet (HSP)
were prepared by subcellular fractionation. A, aliquots of
the HSP (30 µg of protein) and cytosol (20 µg of protein) were
resolved by SDS-PAGE and immunoblotted with antibodies specific for
IRS-1, IRS-2, phosphotyrosine (PY), and PI 3-kinase
(p85). The phosphotyrosine antibody labels a 180-kDa band,
which corresponds to IRS proteins. Immunoreactive IRS-1 ( ), IRS-2
( ), and phosphotyrosine-IRS ( ) present in the HSP (B)
and cytosol fractions (C), respectively, were quantified by
densitometry and expressed as a percentage of the maximum value. The
mean values from at least three independent experiments are shown.
D, immunoreactive GLUT4 present in PM ( ) or HSP ( )
fractions was quantified by densitometry and expressed as a percentage
of the maximum value. The mean values from three independent
experiments are shown.
|
|
Commensurate with the loss of IRS-1 and IRS-2 from the HSP in response
to insulin, we observed a significant increase in the cytosolic
fraction (Fig. 2C). This increase in cytosolic IRS proteins peaked after 1 h of insulin treatment and declined thereafter. We
did not observe a corresponding increase in the level of either IRS-1
or IRS-2 in any other fraction (data not shown), suggesting that this
loss reflects degradation of the IRS proteins. The rate of decline in
cytosolic IRS-1 was considerably more rapid than that of cytosolic
IRS-2, suggesting that the degradation of the two IRS isoforms
following chronic insulin exposure may be controlled by distinct
mechanisms. The release of IRS-1 and IRS-2 from the HSP in response to
insulin was accompanied by a significant decrease in the
electrophoretic mobility of both proteins (Fig. 2A). This was quite evident in the HSP fraction after only 15 min of incubation with insulin. Interestingly, there appeared to be a stepwise decrease in the mobility of both IRS-1 and IRS-2 with time: this was most clearly observed in the cytosol (compare 0.25- versus 1-h
insulin exposure).
To verify the above findings in a heterologous system, CHO cells
overexpressing the IR (CHO-IR) were transfected with a
hemagglutinin-tagged IRS-1 cDNA (HA-IRS-1), and replicated the
above experimental regimen. When expressed in CHO-IR cells, the
HA-IRS-1 protein was tyrosyl-phosphorylated in response to insulin,
suggesting that it forms a competent IR substrate under these
conditions (data not shown). As indicated in Fig.
3A, an anti-HA antibody
immunolabeled a protein that corresponded to a molecular mass of 170 kDa in CHO cells transfected with HA-IRS-1, whereas no specific band
was detected in control cells (not shown). HA-IRS-1 was distributed
between the HSP fraction and the cytosol in CHO cells, consistent with
the distribution of IRS-1 and IRS-2 in adipocytes. Insulin treatment
caused translocation of HA-IRS-1 from the HSP fraction into the cytosol
in CHO-IR cells, with a time course comparable with that observed in
adipocytes (Fig. 3B). After 2 h of insulin treatment,
the level of HA-IRS-1 in the HSP was reduced to <20% of that found
under basal conditions. Initially, there was an increase in HA-IRS-1 in
the cytosol in response to insulin that was presumably derived from the
HSP. However, as was the case in adipocytes for both IRS-1 and IRS-2, after 1 h of prolonged insulin treatment (Fig. 2C), the
level of HA-IRS-1 in the cytosol declined, presumably indicative of net
loss of the protein from the cell. This was not due to nonspecific degradation of the recombinant protein, because in cells maintained at
basal conditions for the 4-h time period, levels of HA-IRS-1 were not
significantly altered (data not shown). These data suggest that the
targeting of IRS-1 to an insoluble intracellular location as well as
its regulated release from this site, can be reconstituted in other
cell types that are not normally considered to be bona fide
insulin-sensitive cells. Whereas chronic insulin treatment caused a
stepwise decrease in the mobility of IRS-1 in the HSP fraction isolated
from 3T3-L1 adipocytes (Fig. 2A), no such change in the
mobility of HA-IRS-1 could be detected in the HSP isolated from CHO-IR
cells (Fig. 3A). This did not appear to be due to an
inability to detect a mobility shift of HA-IRS-1, because a shift was
observed in the mobility of HA-IRS-1 present in the cytosolic pool.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 3.
Effects of chronic insulin treatment on the
subcellular distribution of HA-IRS-1 expressed in CHO-IR cells.
CHO-IR cells were transiently transfected with an HA-tagged IRS-1
cDNA. Cells were incubated with insulin (1 µM) for
different times (0-4 h), lysed, and subjected to differential
centrifugation to obtain the high speed pellet (HSP)
fraction and cytosol. A, aliquots (30 µg) of each fraction
were resolved by SDS-PAGE and immunoblotted with antibodies specific
for HA. B, immunoreactive HA-IRS-1 was quantified by
densitometry, and expressed as a percentage of the maximum value
present in the HSP ( ) or cytosol ( ) fractions. Data shown are
representative of two separate experiments.
|
|
Effects of Wortmannin on the Insulin-dependent Release
of IRS Proteins from the HSP--
To test the role of PI 3-kinase or
of signaling proteins downstream of this enzyme in the
insulin-dependent release of IRS-1 and IRS-2 from the HSP,
we looked at the effects of the PI 3-kinase inhibitor, wortmannin, on
this process. Wortmannin at a concentration of 100 nM had
no significant effect on the insulin-dependent release of
IRS-1 or IRS-2 from the HSP (Fig.
4A). The efficacy of
wortmannin inhibition during these treatments was confirmed by the
absence of an electrophoretic shift in cytosolic Akt-2, a PI
3-kinase-dependent serine kinase (Fig. 4B) (44).
Similar data were obtained using an alternate PI 3-kinase inhibitor,
LY294002 (not shown). While we did not observe a significant effect of
wortmannin on the insulin-stimulated release of IRS proteins in six
experiments, in three of these studies we observed a modest increase in
the amount of IRS-1 and IRS-2 associated with the HSP in cells treated
with wortmannin alone (Fig. 4A). Nevertheless, while these
data suggest that the association of IRS proteins with the HSP may be
regulated by a wortmannin-sensitive factor in the basal state, this is
not the mechanism for the release of IRS proteins in response to
insulin.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 4.
Effects of wortmannin on the insulin-induced
redistribution of IRS proteins in 3T3-L1 adipocytes. Adipocytes
were incubated in the absence or presence of wortmannin (100 nM) for 15 min and then incubated with insulin (1 µM) plus wortmannin (100 nM) for 1 h.
Cells were washed, homogenized, and subjected to differential
centrifugation to obtain high speed pellet (HSP) and cytosol
fractions. A, fractions were resolved by SDS-PAGE and
immunoblotted with antibodies specific for IRS-1 and IRS-2.
B, the cytosolic fraction was resolved by SDS-PAGE and
immunoblotted with antibodies specific for Akt-2. Results
representative of six independent experiments are shown.
|
|
Effects of Okadaic Acid on the Subcellular Distribution of IRS
Proteins--
Okadaic acid, a serine/threonine phosphatase inhibitor,
induces insulin resistance in both adipocytes and muscle cells and potently inhibits insulin-regulated glucose transport by blocking the
translocation of GLUT4 (20, 23, 45, 46). Consistent with these studies,
we also observed a substantial reduction in the level of
insulin-stimulated glucose uptake in 3T3-L1 adipocytes in the presence
of 2.5-5.0 µM okadaic acid (data not shown). In further
agreement with previous studies (23), okadaic acid induced a
significant shift in the electrophoretic mobility of IRS-1 (Fig. 5). Okadaic acid also caused the release
of >90% of IRS-1 from the HSP. This was accompanied by a large
increase in IRS-1 in the cytosol fraction. A similar distribution of
IRS-1 was observed in cells treated with okadaic acid plus insulin
(Fig. 5). Consistent with the hypothesis that the HSP pool of IRS-1
interacts with the IR, we observed no detectable insulin-stimulated
tyrosine phosphorylation of IRS-1 in the cytosol after treatment with
okadaic acid, despite a considerable proportion of the protein in this fraction (Fig. 5). Insulin-stimulated IRS-1 tyrosine phosphorylation in
the HSP fraction after okadaic acid treatment was also significantly decreased and coincided with the large decrease in the IRS-1 protein in
this fraction. This decrease in IRS-1 tyrosine phosphorylation did not
appear to be due to a defect in the IR tyrosine kinase activity,
because insulin-dependent tyrosine phosphorylation of the
IR
-subunit, which is enriched in the plasma membrane fraction (PM), was unaffected by okadaic acid (Fig. 5).

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 5.
Effects of okadaic acid on the subcellular
distribution of IRS-1, PI 3-kinase, and tyrosine phosphoproteins in
3T3-L1 adipocytes. Adipocytes were incubated with okadaic acid
(2.5 µM) for 30 min. Where indicated, insulin was added
for the last 15 min of okadaic acid treatment. Cells were washed and
homogenized, and subcellular fractions were prepared. Aliquots (20 µg) of the plasma membrane (PM), high speed pellet
(HSP), and cytosol (CYT) fractions were resolved
by SDS-PAGE and immunoblotted with antibodies specific for IRS-1
(anti-IRS-1), phosphotyrosine (anti-pY), and PI
3-kinase (anti-p85). Results are representative of two
independent experiments.
|
|
The okadaic acid-induced block in IRS tyrosyl phosphorylation was
accompanied by a decrease in the recruitment of the p85 subunit of PI
3-kinase to the HSP fraction (Fig. 5). While insulin alone stimulated
recruitment of p85 to the HSP, this effect was almost entirely
abolished in the presence of okadaic acid. It is noteworthy that
okadaic acid did not significantly alter the levels of p85 associated
with the HSP fraction in the basal state. This suggests that the
presence of PI 3-kinase in the adipocyte HSP fraction under basal
conditions is probably not mediated by a direct interaction with IRS-1,
and the effects of okadaic acid on the organization of proteins in this
fraction are somewhat specific.
Effects of PDGF on the Subcellular Distribution of IRS
Proteins--
Thus far, we have shown that chronic insulin treatment
and okadaic acid independently trigger the release of IRS proteins from
the adipocyte HSP fraction into the cytosol (Figs. 2 and 5).
Furthermore, both treatments cause a distinct reduction in the
electrophoretic mobility of IRS proteins, both within the HSP fraction
and the cytosol. PDGF has previously been shown to induce a similar
change in the electrophoretic mobility of IRS-1 (47). In addition,
decreases in insulin-stimulated tyrosyl phosphorylation of IRS-1 and
recruitment of PI 3-kinase following PDGF treatment of adipocytes has
been reported (48). We examined the effect of a similar PDGF treatment
protocol on the subcellular distribution of IRS proteins in 3T3-L1
adipocytes. Extended incubation with PDGF (1 h), led to a significant
dissociation of IRS proteins from the HSP (up to 50%), with a
concomitant increase in the cytosolic component (Fig.
6A). However, the magnitude of
this effect was not as great as that observed using chronic insulin
treatment (Fig. 6A). In addition, and unlike the effects of
insulin, we did not observe any detectable electrophoretic shift in
IRS-1 or IRS-2 with PDGF in the HSP, although a noticeable decrease was
observed in the cytosolic fraction. Furthermore, PDGF treatment of
adipocytes did not significantly impair insulin-stimulated glucose
uptake in adipocytes at maximal or submaximal concentrations of insulin
(Fig. 6B). These data suggest that the moderate loss of IRS
proteins from the HSP induced by PDGF does not significantly alter
insulin sensitivity.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 6.
Effects of PDGF on the subcellular
distribution of IRS proteins and insulin-regulated glucose uptake in
3T3-L1 adipocytes. A, adipocytes were incubated with 1 µM insulin (I) or 50 ng/ml PDGF (P)
or no additions (B) for 1 h. Aliquots of the high speed
pellet (HSP) (30 µg) and cytosol (25 µg) were resolved
by SDS-PAGE and immunoblotted with antibodies specific for IRS-1 or
IRS-2. The results shown are representative of three independent
experiments. B, adipocytes were incubated in the absence or
presence of 50 ng/ml PDGF for 1 h and subsequently treated with
insulin at the noted concentrations for 15 min. 2-deoxyglucose
(2-DOG) uptake was measured in the final 3 min of treatment
as outlined under "Experimental Procedures." The results depict the
mean ± S.D. of duplicates for each condition and are
representative of two independent experiments.
|
|
 |
DISCUSSION |
The strength, duration, and specificity of growth factor signaling
may be accomplished, at least in part, by the spatial
compartmentalization of the cognate signal transduction machinery. In
accordance with this notion, we and others have previously reported
that a cohort of insulin-regulatable signaling proteins, including
IRS-1, associate with a low density insoluble fraction in basal
adipocytes (29, 31, 33, 40) that we refer to as the HSP. Biochemical
analyses of the HSP indicates that IRS-1 does not associate with
membranes in this fraction (29). In contrast to HSP-associated membrane proteins, such as GLUT4, IRS-1 remains insoluble in nonionic detergents and does not exhibit buoyant density in sucrose gradients. The latter
observation is of particular note, because it excludes the possibility
that IRS-1 associates with modified vesicular structures such as
caveolae or clathrin-coated vesicles (49, 50). In addition to
membranes, the HSP contains large protein complexes and cytoskeletal
elements (29). Thus, we have proposed that IRS-1 is associated with the
cytoskeleton and that this protein complex co-fractionates with
intracellular membranes. In this study, we have shown that IRS-2 has
similar properties to IRS-1. A significant proportion of IRS-2
co-fractionates in the HSP (Fig. 1A), consistent with other
studies (34, 43); IRS-2 remains insoluble in nonionic detergents (Fig.
1B), and IRS-2 does not float in dense sucrose solutions
(data not shown). Hence, we conclude that IRS-1 and IRS-2 associate
with a large protein complex in the basal state that has properties
characteristic of the cytoskeleton.
What is the function of the HSP pool of IRS proteins? There are several
indications that the HSP represents the location where insulin
signaling is initiated. First, the largest increase in insulin-stimulated IRS protein-tyrosine phosphorylation occurs in the
HSP (Fig. 2, A and B). Second, the increase in
tyrosyl-phosphorylated IRS proteins in the HSP correlates with the
recruitment of PI 3-kinase to this fraction from the cytosol (Fig.
2A). Third, okadaic acid results in an almost quantitative
release of IRS-1 from the HSP into the cytosol, and, despite
maintenance of the IR tyrosine kinase activity (20), there is no
detectable insulin-stimulated tyrosine phosphorylation of IRS proteins
in the cytosol (Fig. 5). One initial signaling event is the interaction
with the IR, and we suggest that the cytoskeletal localization of IRS
proteins that is present in the HSP may be required for this to occur
efficiently. Considerable evidence suggests that IRS-1 encounters the
IR at the plasma membrane, so we have proposed that this HSP pool of IRS-1 represents a cytoskeleton that decorates the underside of the
plasma membrane. First, immunofluorescence localization of tyrosyl-phosphorylated IRS-1 in CHO cells indicates that at early times
(~1 min), after insulin addition there is cell surface labeling, followed by increased cytosolic staining at later times (51). Second,
inhibition of endocytosis by incubation at 4 °C (31), potassium
depletion (52), or use of a mutant dynamin allele has little effect on
insulin-stimulated tyrosine phosphorylation of either IR or IRS-1 (53).
Finally, microinjection of a fusion protein that specifically interacts
with the phosphatidylinositide product of PI 3-kinase activity, PI
3,4,5-trisphosphate, into adipocytes showed pronounced labeling of the
plasma membrane within 1 min of insulin stimulation (54). Hence, the
localization of IRS-1 and IRS-2 to the cytoskeleton underlying the
plasma membrane may allow an efficient interaction between the
pleckstrin homology and phosphotyrosine binding domains of these
proteins with the intracellular tail of the IR and thus rapidly
promotes tyrosine phosphorylation of these proteins in response to
insulin. Furthermore, the coordination of these signaling events with
the recruitment of PI 3-kinase may ensure the correct localization of
this enzyme to its membrane-bound substrate(s), located at the cell surface.
It has previously been shown that with short term insulin treatment,
IRS-1 translocates from the HSP into the cytosol in 3T3-L1 adipocytes
(31). One possibility is that this translocation event may be necessary
to propagate the insulin signal by allowing the IRS-signaling complex
access to the relevant downstream targets. This does not appear to be
the case, at least for PI 3-kinase, given that downstream targets of
this enzyme are recruited to the cell surface (54). Alternatively, this
translocation event may act as the "off" switch for insulin action.
This implies that the inappropriate release of IRS proteins into the
cytosol may disengage IR and IRS proteins, resulting in desensitization
and/or insulin resistance. In support of this model, we have shown that exposure of adipocytes to conditions known to cause insulin resistance, namely chronic insulin or okadaic acid treatment, also stimulate the
release of IRS proteins from the HSP into the cytosol (Figs. 2 and 5, respectively).
PDGF treatment caused a relatively modest decline in IRS levels in the
HSP (Fig. 6A), whereas the loss with okadaic acid treatment was almost quantitative (Fig. 5). This is an important distinction to
make, because preincubation of adipocytes with PDGF for 60 min prior to
insulin treatment does not impair insulin-stimulated glucose transport
(Fig. 6B) (48), while okadaic acid potently inhibits this
process (20, 23, 45, 46). Similarly, the onset of insulin resistance in
cells exposed to chronic insulin treatment coincides with the loss of
more than 90% of IRS protein from the HSP (Fig. 2). These data suggest
that there is a nonlinear relationship between the level of IRS protein
associated with the HSP and the onset of insulin resistance and that a
small amount of IRS proteins associated with the HSP is sufficient to
evoke a full biological response to insulin. We propose that a
competent level of IRS proteins is maintained in the HSP in the
presence of short term PDGF treatment and during several hours of
insulin treatment. However, this threshold cannot be maintained in
response to longer insulin treatment or okadaic acid.
In each of the three experimental regimens used to challenge the
localization of IRS proteins, the function of the insulin receptor
appears to be retained, but the insulin-regulated tyrosyl phosphorylation of IRS proteins is decreased (20, 21, 24, 48). This
observation can be explained based on the model proposed here, where
the translocation of IRS proteins from the HSP into the cytosol
uncouples their phosphorylation from the insulin receptor simply due to
inaccessibility. The possibility that other mechanisms disrupt IR
phosphorylation of IRS proteins in the cytosol, such as an interaction
between IRS proteins with cytosolic factors or covalent modification of
IRS proteins, cannot be discounted. The latter mechanism is thought to
be invoked during tumor necrosis factor-
-induced insulin resistance
in adipocytes. Tumor necrosis factor-
leads to increased serine
phosphorylation of IRS-1 and decreased tyrosine phosphorylation of
IRS-1 by the insulin receptor (22). Enhanced Ser/Thr phosphorylation of
IRS proteins has been proposed to alter the mobility of these molecules
during SDS-PAGE and has been observed in cells exposed to each of the
conditions employed in these studies (23, 24, 47). Interestingly, we routinely observed the most significant gel shift in the cytosolic pool
of IRS proteins exposed to chronic insulin treatment (Fig. 2A), okadaic acid (Fig. 5), or PDGF (Fig. 6A).
Ser/Thr phosphorylation of IRS proteins has also been proposed to
trigger the translocation of these molecules into the cytosol (31).
However, in wortmannin-treated adipocytes, the electrophoretic shift of
IRS proteins in response to prolonged insulin stimulation was blunted,
but the translocation to the cytosol was not impaired (Fig.
4A), suggesting that the two processes can be uncoupled.
This is in agreement with recent studies by Inoue and colleagues (34),
where the release of IRS proteins from the HSP has been attributed to
the phosphorylation of other proteins contained within this fraction.
It is plausible that serine phosphorylation of IRS proteins occurs
simultaneously with release from the HSP as a mechanism to prevent
inappropriate interactions with IR. This would ensure accurate
termination of the insulin signal as well as avoiding mislocalization
of downstream targeting molecules.
It is conceivable that insulin resistance induced by the shift of IRS
proteins from the HSP may result from one of two mechanisms in
adipocytes. The first mechanism, which may occur very rapidly and is
presumably promoted by okadaic acid, involves the disengagement of IR
from IRS proteins. The second mechanism involves down-regulation of the
relevant signaling molecules. This mechanism may require a longer
duration to take effect than the first but may be equipotent in terms
of the long term potential to induce insulin resistance. Recent studies
have shown that prolonged insulin stimulation decreases the half-life
of IRS-1 from 20 to 2.5 h in 3T3-L1 adipocytes (55). In agreement
with these findings, we also observed a net loss of IRS-1 and IRS-2
with chronic insulin treatment (Figs. 2, A-C). These
observations raise the possibility that release of IRS proteins into
the cytosol increases the accessibility to proteases responsible for
their down-regulation. This catabolic state may only be evident under
extreme circumstances, whereas during normal conditions of transient
insulin elevations, IRS proteins may rapidly recycle between the HSP
and cytosol without significant degradation. The calcium-dependent proteases of the calpain family have been
implicated in the degradation of IRS proteins (56). It is equally
possible that the regulated movement of IRS-1 and IRS-2 corresponds to an increase in the ubiquitination of these
proteins.2 In this regard,
the incremental increases in the molecular weight of cytosolic IRS-1
and IRS-2 observed in response to chronic insulin (Fig. 2A),
okadaic acid (Fig. 5), and PDGF (Fig. 6A) may correspond to
mono- or polyubiquitination of these proteins.
Based on the present studies, we suggest that the intracellular
localization of the insulin-specific docking proteins IRS-1 and -2 may
play an important role in modulating insulin signaling cascades.
Identification of the downstream signaling molecules that mediate many
of insulin's specific actions, such as GLUT4 translocation to the cell
surface, remain an important challenge. However, equally important will
be the identification of the factors in the HSP that anchor IRS
proteins within close proximity of the insulin receptor and
subsequently enhance the efficiency of signaling in response to insulin stimulation.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Nia Bryant, Michelle Hill, and
Shane Rea for critical reading of this manuscript. We also thank Sara
Smith and Shane McIntosh for the construction of HA-IRS-1 cDNA and
Teresa Munchow for tissue culture. We also thank Drs. Susanna Keller and Gus Lienhard for the generous gift of IRS-1 cDNA, Dr. Morris White for the gift of CHO-IR cells, and Dr. Brian Druker for the gift
of antibodies.
 |
FOOTNOTES |
*
This work was supported by the Juvenile Diabetes Foundation
International and the National Health and Medical Research Council of
Australia.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The first two authors contributed equally to this work.
§
To whom correspondence should be addressed: Tel.: 61 7 3365 4986;
Fax: 61 7 3365 4430; E-mail: D.James@cmcb.uq.edu.au.
2
Evidence implicating the involvement of a
ubiquitin-dependent pathway in the degradation of IRS-1 was
reported by Sun et al. (57) while this manuscript was in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
IR, insulin
receptor;
IRS, insulin receptor substrate;
PI, phosphatidylinositide;
PDGF, platelet-derived growth factor;
CHO, Chinese hamster ovary;
HSP, high speed pellet;
HA, hemagglutinin;
PAGE, polyacrylamide gel
electrophoresis;
PBS, phosphate-buffered saline.
 |
REFERENCES |
| 1.
|
White, M. F.,
and Kahn, C. R.
(1994)
J. Biol. Chem.
269,
1-4[Free Full Text]
|
| 2.
|
Lavan, B. E.,
Lane, W. S.,
and Lienhard, G. E.
(1997)
J. Biol. Chem.
272,
11439-11443[Abstract/Free Full Text]
|
| 3.
|
Lavan, B. E.,
Fantin, V. R.,
Chang, E. T.,
Lane, W. S.,
Keller, S. R.,
and Lienhard, G. E.
(1997)
J. Biol. Chem.
272,
21403-21407[Abstract/Free Full Text]
|
| 4.
|
Sun, X. J.,
Rothenberg, P.,
Kahn, C. R.,
Backer, J. M.,
Araki, E.,
Wilden, P. A.,
Cahill, D. A.,
Goldstein, B. J.,
and White, M. F.
(1991)
Nature
352,
73-77[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Sun, X. J.,
Wang, L. M.,
Zhang, Y. T.,
Yenush, L.,
Myers, M. G.,
Glasheen, E.,
Lane, W. S.,
Pierce, J. H.,
and White, M. F.
(1995)
Nature
377,
173-177[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Gustafson, T. A.,
He, W.,
Craparo, A.,
Schaub, C. D.,
and O'Neill, T. J.
(1995)
Mol. Cell. Biol.
15,
2500-2508[Abstract]
|
| 7.
|
Yenush, L.,
Makati, K. J.,
Smith-Hall, J.,
Ishibashi, O.,
Myers, M. G.,
and White, M. F.
(1996)
J. Biol. Chem.
271,
24300-24306[Abstract/Free Full Text]
|
| 8.
|
Ogawa, W.,
Matozaki, T.,
and Kasuga, M.
(1998)
Mol. Cell. Biochem.
82,
13-22
|
| 9.
|
Lavan, B. E.,
Kuhne, M. R.,
Garner, C. W.,
Anderson, D.,
Reedijk, M.,
Pawson, T.,
and Lienhard, G. E.
(1992)
J. Biol. Chem.
267,
11631-11636[Abstract/Free Full Text]
|
| 10.
|
Sun, X. J.,
Crimmins, D. L.,
Myers, M. J.,
Miralpeix, M.,
and White, M. F.
(1993)
Mol. Cell. Biol.
13,
7418-7428[Abstract/Free Full Text]
|
| 11.
|
Okada, T.,
Kawano, Y.,
Sakakibara, T.,
Hazeki, O.,
and Ui, M.
(1994)
J. Biol. Chem.
269,
3568-3573[Abstract/Free Full Text]
|
| 12.
|
Cheatham, B.,
Vlahos, C. J.,
Cheatham, L.,
Wang, L.,
Blenis, J.,
and Kahn, C. R.
(1994)
Mol. Cell. Biol.
14,
4902-4911[Abstract/Free Full Text]
|
| 13.
|
Kotani, K.,
Carozzi, A. J.,
Sakaue, H.,
Hara, K.,
Robinson, L. J.,
Clark, S. F.,
Yonezawa, K.,
James, D. E.,
and Kasuga, M.
(1995)
Biochem. Biophys. Res. Commun.
209,
343-348[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Quon, M. J.,
Chen, H.,
Ing, B. L.,
Liu, M. L.,
Zarnowski, M. J.,
Yonezawa, K.,
Kasuga, M.,
Cushman, S. W.,
and Taylor, S. I.
(1995)
Mol. Cell. Biol.
5,
5403-5411
|
| 15.
|
Keller, S. R.,
Kitagawa, K.,
Aebersold, R.,
Lienhard, G. E.,
and Garner, C. W.
(1991)
J. Biol. Chem.
266,
12817-12820[Abstract/Free Full Text]
|
| 16.
|
Craparo, A.,
Freund, R.,
and Gustafson, T. A.
(1997)
J. Biol. Chem.
272,
11663-11669[Abstract/Free Full Text]
|
| 17.
|
Ogihara, T.,
Isobe, T.,
Ichimura, T.,
Taoka, M.,
Funaki, M.,
Sakoda, H.,
Onishi, Y.,
Inukai, K.,
Anai, M.,
Fukushima, Y.,
Kikuchi, M.,
Yazaki, Y.,
Oka, Y.,
and Asano, T.
(1997)
J. Biol. Chem.
272,
25267-25274[Abstract/Free Full Text]
|
| 18.
|
De Fronzo, R. A.,
Bonadonna, R. C.,
and Ferrannini, E.
(1992)
Diabetes Care
15,
318-368[Abstract]
|
| 19.
|
Hotamisligil, G. S.,
Peraldi, P.,
Budavari, A.,
Ellis, R.,
White, M. F.,
and Spiegelman, B. M.
(1996)
Science
271,
665-668[Abstract]
|
| 20.
|
Tanti, J.-F.,
Gremeaux, T.,
Cormont, M.,
Van Obberghen, E.,
and Le Marchand-Brustel, Y.
(1993)
Am. J. Physiol.
64,
E868-E873
|
| 21.
|
Kozka, I. J.,
Clark, A. E.,
and Holman, G. D.
(1991)
J. Biol. Chem.
266,
11726-11731[Abstract/Free Full Text]
|
| 22.
|
Hotamisligil, G. S.,
Murray, D. L.,
Choy, L. N.,
and Spiegelman, B. M.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
4854-4858[Abstract/Free Full Text]
|
| 23.
|
Tanti, J. F.,
Gremeaux, T.,
Van Obberghen, E.,
and Le Marchand-Brustel, Y.
(1994)
J. Biol. Chem.
269,
6051-6057[Abstract/Free Full Text]
|
| 24.
|
Ricort, J-M.,
Van Obberghen, E.,
and Le Marchand-Brustel, Y.
(1995)
Diabetologia
38,
1148-1156[Medline]
[Order article via Infotrieve]
|
| 25.
|
Eldar-Finkelman, H.,
and Krebs, E. G.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
9660-9664[Abstract/Free Full Text]
|
| 26.
|
Chin, J. E.,
Liu, F.,
and Roth, R. A.
(1994)
Mol. Endocrinol.
8,
51-58[Abstract]
|
| 27.
|
De Fea, K.,
and Roth, R. A.
(1997)
J. Biol. Chem.
272,
31400-31406[Abstract/Free Full Text]
|
| 28.
|
Li, J.,
DeFea, K.,
and Roth, R. A.
(1999)
J. Biol. Chem.
274,
9351-9356[Abstract/Free Full Text]
|
| 29.
|
Clark, S. F.,
Martin, S.,
Carozzi, A. J.,
Hill, M. M.,
and James, D. E.
(1998)
J. Cell Biol.
140,
1211-1225[Abstract/Free Full Text]
|
| 30.
|
Kelly, K. L.,
and Ruderman, N. B.
(1993)
J. Biol. Chem.
268,
4391-4398[Abstract/Free Full Text]
|
| 31.
|
Heller-Harrison, R. A.,
Morin, M.,
and Czech, M. P.
(1995)
J. Biol. Chem.
270,
24442-24450[Abstract/Free Full Text]
|
| 32.
|
Wiese, R. J.,
Mastick, C. C.,
Lazar, D. F.,
and Saltiel, A. R.
(1995)
J. Biol. Chem.
270,
3442-3446[Abstract/Free Full Text]
|
| 33.
|
Kublaoui, B.,
Lee, J.,
and Pilch, P. F.
(1995)
J. Biol. Chem.
270,
59-65[Abstract/Free Full Text]
|
| 34.
|
Inoue, G.,
Cheatham, B.,
Emkey, R.,
and Kahn, C. R.
(1998)
J. Biol. Chem.
273,
11548-11555[Abstract/Free Full Text]
|
| 35.
|
James, D. E.,
Brown, R.,
Navarro, J.,
and Pilch, P. F.
(1988)
Nature
333,
183-185[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Benito, M.,
Porras, A.,
Nebrada, A. R.,
and Santos, E.
(1991)
Science
253,
565- 568[Abstract/Free Full Text]
|
| 37.
|
Piper, R. C.,
Hess, L. J.,
and James, D. E.
(1991)
Am. J. Physiol.
260,
C570-C580[Abstract/Free Full Text]
|
| 38.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Robinson, L. J.,
Razzack, Z. F.,
Lawrence, J. C.,
and James, D. E.
(1993)
J. Biol. Chem.
268,
26422-26427[Abstract/Free Full Text]
|
| 40.
|
Ricort, J-M.,
Tanti, J. F.,
Van Obberghen, E.,
and Le Marchand-Brustel, Y.
(1996)
Eur. J. Biochem.
239,
17-22[Medline]
[Order article via Infotrieve]
|
| 41.
|
Hill, M. M.,
Clark, S. F.,
and James, D. E.
(1997)
Electrophoresis
18,
2629-2637[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Zhou, L.,
Chen, L.,
Lin, C. H.,
Cong, L.-N.,
McGibbon, M. A.,
Sciacchitano, S.,
Lesniak, M. A.,
Quon, M. J.,
and Taylor, S. I.
(1997)
J. Biol. Chem.
272,
29829-29833[Abstract/Free Full Text]
|
| 43.
|
Anai, O.,
Ono, H.,
Funaki, M.,
Fukushima, Y.,
Inukai, K.,
Ogihara, T.,
Sakoda, H.,
Onishi, Y.,
Yazaki, Y.,
Kikuchi, M.,
Oka, Y.,
and Asano, T.
(1998)
J. Biol. Chem.
273,
29686-29692[Abstract/Free Full Text]
|
| 44.
|
Burgering, B.,
and Coffer, P. J.
(1995)
Nature
376,
599-602[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Jullien, D.,
Tanti, J-F.,
Heydrick, S. J.,
Gautier, N.,
Gremeaux, T.,
Van Obberghen, E.,
and Le Marchand-Brustel, Y.
(1993)
J. Biol. Chem.
268,
15246-15251[Abstract/Free Full Text]
|
| 46.
|
Lawrence, J. C., Jr.,
Hiken, J. F.,
and James, D. E.
(1990)
J. Biol. Chem.
265,
19768-19776[Abstract/Free Full Text]
|
| 47.
|
Ricort, J-M.,
Tanti, J-F.,
Van Obberghen, E.,
and Le Marchand-Brustel, Y.
(1997)
J. Biol. Chem.
272,
19814-19818[Abstract/Free Full Text]
|
| 48.
|
Staubs, P. A.,
Nelson, J. G.,
Reichart, D. R.,
and Olefsky, J. M.
(1998)
J. Biol. Chem.
273,
25139-25147[Abstract/Free Full Text]
|
| 49.
|
Pearse, B. M. F.
(1982)
Proc. Natl. Acad. Sci. U. S. A.
79,
451-455[Abstract/Free Full Text]
|
| 50.
|
Kurchalia, T.,
Dupree, P.,
Parton, R. G.,
Kellner, R.,
Virta, H.,
Lehnert, M.,
and Simons, K.
(1992)
J. Cell Biol.
118,
1003-1014[Abstract/Free Full Text]
|
| 51.
|
Sun, X. J.,
Miralpeix, M.,
Myers, M., Jr.,
Glasheen, E. M.,
Backer, J. M.,
Kahn, C. R.,
and White, M. F.
(1992)
J. Biol. Chem.
267,
22662-22672[Abstract/Free Full Text]
|
| 52.
|
Biener, Y.,
Feinstein, R.,
Mayak, M.,
Kaburagi, Y.,
Kadowaki, T.,
and Zick, Y.
(1996)
J. Biol. Chem.
271,
29489-29496[Abstract/Free Full Text]
|
| 53.
|
Ceresa, B. P.,
Kao, A. W.,
Santeler, S. R.,
and Pessin, J. E.
(1998)
Mol. Cell. Biol.
18,
3862-3870[Abstract/Free Full Text]
|
| 54.
|
Venkateswarlu, K.,
Oatey, P. B.,
Tavare, J. M.,
and Cullen, P. J.
(1998)
Curr. Biol.
8,
463-466[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Rice, K. M.,
Turnbow, M. A.,
and Garner, C. W.
(1993)
Biochem. Biophys. Res. Commun.
190,
961-967[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Smith, L. K.,
Rice, K. M.,
and Garner, C. W.
(1996)
Mol. Cell. Endocrinol.
122,
81-92[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Sun, X. J.,
Goldberg, J. L.,
Qiao, L. Y.,
and Mitchell, J. J.
(1999)
Diabetes
48,
1359-1364[Abstract]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
X. Su, I. J. Lodhi, A. R. Saltiel, and P. D. Stahl
Insulin-stimulated Interaction between Insulin Recept |